[1] Finn RS, Qin SK, Ikeda M, et al. Atezolizumab plus bevacizumab

in unresectable hepatocellular carcinoma[J]. N Engl J Med, 2020,

382(20): 1894-1905. DOI: 10.1056/NEJMoa1915745.

[2] Cheng A, Qin S, Ikeda M, et al. Atezolizumab + bevacizumab vs

sorafenib in patients with unresectable hepatocellular carcinoma:

phase 3 results from IMbrave150[C]. ESMO Asia Congress, 2019:

abstract LBA1.

[3] Xu J, Shen J, Gu S. et al. Camrelizumab in combination with

apatinib in patients with advanced hepatocellular carcinoma

(RESCUE): a nonrandomized, open-label, phase II trial[J]. Clin

Cancer Res, 2021, 27(4): 1003-1011. DOI: 10.1158/1078-0432.

CCR-20-2571.

[4] Qin S, Ren Z, Feng Z, et al. Efficacy and safety of atezolizumab+

bevacizumab vs sorafenib in Chinese patients with unresectable

HCC in the phase Ⅲ IMbrave150 study[C]. Liver Cancer Summit,

2020: abstract OP02-03.

[5] Finn RS, Ikeda M, Zhu AX, et al. Phase Ib study of lenvatinib

plus pembrolizumab in patients with unresectable hepatocellular

carcinoma[J]. J Clin Oncol, 2020, 38(26): 2960-2970. DOI: 10.1200/

JCO.20.00808.

[6] kudo M, Ikeda M, Motomura K, et al. A phase 1b study of lenvatinib

plus nivolumab in patients with unresectable hepatocellular carcinoma

(study 117)[C]. ASCO Gastrointestinal Cancers Symposium, 2020:

Abstract 513.

[7] Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk

factors in China and its provinces, 1990-2017: a systematic analysis

for the Global Burden of Disease Study 2017[J]. Lancet, 2019,

394(10204): 1145-1158. DOI: 10.1016/S0140-6736(19)30427-1.

[8] Allemani C, Weir Hk, Carreira H, et al. Global surveillance of

cancer survival 1995-2009: analysis of individual data for 25, 676,

887 patients from 279 population-based registries in 67countries[J].

Lancet, 2015, 385(9972): 977-1010. DOI: 10.1016/S0140-

6736(14)62038-9.

[9] Torre LA, Bray F, Siegel R et al. Global cancer statistics, 2012[J].

CA Cancer J Clin, 2015, 65(2): 87-108. DOI: 10.3322/caac.21262.

[10] Chen W, Zheng R, Baade Pd, et al. Cancer statistics in China,

2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132. DOI: 10.3322/

caac.21338.

[11] Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global

cancer incidence and mortality in 2018: GLOBOCAN sources and

methods. Int J Cancer, 2019, 144(8): 1941-1953. DOI: 10.1002/

ijc.31937.

[12] Lovet J, Ricci S, Vincenzo M, et al. Sorafenib in advanced

hepatocellular carcinoma[J]. N Engl J Med, 2008, 359 (4): 378-390.

DOI: 10.1056/NEJMoa0708857.

[13] Cheng A, Kang Y, Chen Z, et al. Efficacy and safety of sorafenib

in patients in the Asia-Pacific region with advanced hepatocellular

carcinoma: a phase Ⅲ randomised, double-blind, placebo-controlled

trial[J]. Lancet Oncol, 2009, 10 (1): 25-34. DOI: 10.1016/S1470-

2045(08)70285-7.

[14] Kudo M, Finn R, Qin S, et al. Lenvatinib versus sorafenib in first-

line treatment of patients with unresectable hepatocellular carcinoma:

a randomised phase 3 non-inferiority trial[J]. Lancet. 2018,

391(10126): 1163-1173. DOI: 10.1016/S0140-6736(18)30207-1.

[15] Bruix J, Qin S, Merle P, et al. Regorafenib for patients with

hepatocellular carcinoma who progressed on sorafenib treatment

(RESORCE): a randomised, double-blind, placebo-controlled, phase

3 trial[J]. Lancet, 2017, 389(10064): 56-66. DOI: 10.1016/S0140-

6736(16)32453-9.

[16] Aboualfa G, Meyer T, Cheng A, et al. Cabozantinib in patients with

advanced and progressing hepatocellular carcinoma[J]. N Engl J

Med, 2018, 379(1): 54-63. DOI: 10.1056/NEJMoa1717002.

[17] Zhu AX, Kang YK, Yen CJ, et al. Ramucirumab after sorafenib

in patients with advanced hepatocellular carcinoma and increased

α-fetoprotein concentrations (REACH-2): a randomised, double-

blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2019,

20(2): 282-296. DOI: 10.1016/S1470-2045(18)30937-9.

[18] 中華人民共和國國家衛(wèi)生健康委員會醫(yī)政醫(yī)管局 . 原發(fā)性肝癌

診療規(guī)范 (2019 年版 )[J]. 中國實用外科雜志 , 2020, 40(2): 121-

138.

[19] 中國臨床腫瘤學會指南工作委員會 . 中國臨床腫瘤學會

（CSCO）原發(fā)性肝癌診療指南 2020[M]. 北京 : 人民衛(wèi)生出版社 ,

2020.

[20] Ren Z, Fan J, Xu J, et al. Sintilimab plus bevacizumab biosimilar

vs sorafenib as first-line treatment for advanced hepatocellular

carcinoma (ORIENT-32)[C]. ESMO Asia Virtual Congress, 2020:

LBA2.

[21] Qin S, Chen Z, Liu Y, et al. A phase Ⅱ study of anti-PD-1 antibody

camrelizumab plus FOLFOX4 or GEMOX systemic chemotherapy

as first-line therapy for advanced hepatocellular carcinoma or biliary

tract cancer[J]. J Clin Oncol, 2019, 37 (s): abstract 4074.

[22] Zhu A, Finn R, Edeline J, et al. Pembrolizumab in patients with

advanced hepatocellular carcinoma previously treated with

sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2

trial[J]. Lancet Oncol, 2018, 19(7): 940-952. DOI: 10.1016/S1470-

2045(18)30351-6.

[23] Jiao SC, Bai L, Dong JH, et al. Clinical activity and safety of

penpulimab (Anti-PD-1) with anlotinib as first-line therapy for

advanced hepatocellular carcinoma (HCC)[J]. J Clin Oncol, 2020,

38(15_suppl):4592. DOI:10.1200/JCO.2020.38.15_suppl.4592.

[24] Hui-Chuan S, Xiao-Dong Z, Cheng H, et al. Initially unresectable

hepatocellular carcinoma treated by combination therapy of tyrosine

kinase inhibitor and anti-PD-1 antibody followed by resection[C].

2020 ASCO Annual Meeting, 2020.

[25] 張雯雯 , 胡丙洋 , 韓駿 , 等 . PD-1 抑制劑與多靶點酪氨酸激酶

抑制劑聯(lián)合方案用于進展期肝癌轉化治療研究的初步報告 [J].

中華肝膽外科雜志 , 2020, 26(12): 947-948. DOI: 10.3760/cma.

j.cn113884-20201203-00611.

[26] Qin S, Ren Z, Meng Z, et al. Camrelizumab in patients with previously

treated hepatocellular carcinoma: a multicenter, randomized, open-

label, parallel-group, phase 2 trial[J]. Lancet Oncol, 2020, 21(4): 571-

580. DOI: 10.1016/S1470-2045(20)30011-5.

[27] Michel D, Ghassan A, Ren Z, et al. Results from a global Phase 2

study of tislelizumab, an investigational PD-1 antibody, in patients

with previously treated advanced hepatocellular carcinoma[C].

WCGI, 2021: O-1.

[28] Bruix J, Fonseca L, Reig M. Insights into the success and failure

of systemic therapy for hepatocellular carcinoma[J]. Nat Rev

Gastroenterol Hepatol, 2019, 16(10): 617-630. DOI: 10.1038/

s41575-019-0179-x.

[29] Llovet J, Kelley R, Villanueva A, et al. Hepatocellular carcinoma[J].

Nat Rev Dis Primers, 2021, 7(1): 6. 41572-020-00240-3. DOI:

10.1038/s41572-020-00240-3.

[30] Ei-khoueiry A, Sangro B, Yau T, et al. Nivolumab in patients with

advanced hepatocellular carcinoma (CheckMate 040): an open-label,

non-comparative, phase 1/2 dose escalation and expansion trial[J].

Lancet, 2017, 389 (10088): 2492-2502. DOI: 10.1016/S0140-

6736(17)31046-2.

[31] Finn R, Ryoo B, Merle P, et al. Pembrolizumab as second-line

therapy in patients with advanced hepatocellular carcinoma in

KEYNOTE-240: a randomized, double-blind, phase III trial[J]. J

Clin Oncol, 2020, 38(3): 193-202. DOI: 10.1200/JCO.19.01307.

[32] Xu J, Zhang Y, Jia R, et al. Anti-PD-1 antibody SHR-1210 combined

with apatinib for advanced hepatocellular carcinoma, gastric, or

esophagogastric junction cancer: an open-label, dose escalation and

expansion study[J]. Clin Cancer Res, 2019, 25(2): 515-523. DOI:

10.1158/1078-0432.CCR-18-2484.

[32] Shen L, Guo J, Zhang Q, et al. Tislelizumab in Chinese patients with

advanced solid tumors: an open-label, non-comparative, phase 1/2

study[J]. J Immunother Cancer, 2020, 8(1): e000437. DOI: 10.1136/

jitc-2019-000437.

[33] Yau T, Kang Y, Kim T, et al. Efficacy and safety of nivolumab plus

ipilimumab in patients with advanced hepatocellular carcinoma

previously treated with sorafenib: the checkmate 040 randomized

clinical trial[J]. JAMA Oncol. 2020, 6(11): e204564. DOI: 10.1001/

jamaoncol.2020.4564.

[34] Kelley R, Sangro B, Harris W, et al. Efficacy, tolerability, and

biologic activity of a novel regimen of tremelimumab in combination

with durvalumab for patients with advanced hepatocellular

carcinoma[J]. J Clin Oncol, 2020, 37(S): 4508. DOI: 10.1200/

JCO.2020.38.15_suppl.4508.

[35] Mrl L, Nipp R, Muzikansky A, et al. Impact of age on outcomes

with immunotherapy in patients with non-small cell lung

cancer[J]. J Thorac Oncol，2019, 14(3): 547-552. DOI: 10.1016/

j.jtho.2018.11.011.

[36] Wolchok J, Hoos A, O'Day S, et al. Guidelines for the evaluation of

immune therapy activity in solid tumors: immune-related response

criteria[J]. Clin Cancer Res, 2009, 15(23): 7412-7420. DOI:

10.1158/1078-0432.CCR-09-1624.

[37] Somarouthu B, Lee S, Urban T, et al. Immune-related tumour

response assessment criteria: a comprehensive review[J]. Br J

Radiol, 2018, 91(1084): 20170457. DOI: 10.1259/bjr.20170457.

[38] Cook M, Kim C. Safety and efficacy of immune checkpoint inhibitor

therapy in patients with HIV infection and advanced-stage cancer:

a systematic review[J]. JAMA Oncol 2019, 5(7): 1049-1054. DOI:

10.1001/jamaoncol.2018.6737.

[39] 中國臨床腫瘤學會指南工作委員會 . 中國臨床腫瘤學會 (CSCO)

免疫檢查點抑制劑相關的毒性管理指南 [M]. 北京 : 人民衛(wèi)生出

版社 , 2019.

[40] Michot J, Bigenwald C, Champiat S, et al. Immune-related adverse

events with immune checkpoint blockade: a comprehensive

review[J]. Eur J Cancer, 2016, 54: 139-148. DOI: 10.1016/

j.ejca.2015.11.016.

[41] Pillai R, Behera M, Owonikoko T, et al. Comparison of the toxicity

profile of PD-1 versus PD-L1 inhibitors in non-small cell lung

cancer: a systematic analysis of the literature[J]. Cancer, 2018,

124(2): 271-277. DOI: 10.1002/cncr.31043.

[42] 中華醫(yī)學會感染病學分會 , 中華醫(yī)學會肝病學分會 . 慢性乙型

肝炎防治指南 (2019 年版 )[J]. 中華傳染病雜志 , 2019, 37(12):

711-736. DOI: 10.3760/cma.j.issn.1000-6680.2019.12.003.

[43] 中華醫(yī)學會肝病學分會 , 中華醫(yī)學會感染病學分會 . 丙型肝炎

防治指南 (2019 年版 )[J]. 中華臨床感染病雜志 , 2019, 12(6):

429-450. DOI: 10.3760/cma.j.issn.1007-3418.2019.12.008.

[44] Pawlotsky J, Negro F, Aghemo A, et al. EASL recommendations on

treatment of hepatitis C 2018[J]. J Hepatol, 2018, 69 (2): 373-395.

DOI: 10.1016/j.jhep.2018.03.026.

[45] Kim W, Loomba R, Berg T, et al. Impact of long-term tenofovir

disoproxil fumarate on incidence of hepatocellular carcinoma in

patients with chronic hepatitis B[J]. Cancer, 2015, 121 (20): 3631-

3638. DOI: 10.1002/cncr.29537.

[46] Huang G, Lau W, Wang Z, et al. Antiviral therapy improves

postoperative survival in patients with hepatocellular carcinoma: a

randomized controlled trial[J]. Ann Surg, 2015, 261 (1): 56-66. DOI:

10.1097/SLA.0000000000000858.

[47] Papatheodoridis G, Idilman R, Dalekos G, et al. The risk of

hepatocellular carcinoma decreases after the first 5 years of entecavir

or tenofovir in Caucasians with chronic hepatitis B[J]. Hepatology,

2017, 66 (5): 1444-1453. DOI: 10.1002/hep.29320.

[48] Chan H, Fung S, Seto W, et al. Tenofovir alafenamide versus

tenofovir disoproxil fumarate for the treatment of HBeAg-positive

chronic hepatitis B virus infection: a randomised, doubleblind, phase

3, non-inferiority trial[J]. Lancet Gastroenterol Hepatol, 2016, 1 (3) :

185-195. DOI: 10.1016/S2468-1253(16)30024-3.

[49] Buti M, Gane E, Seto W, et al. Tenofovir alafenamide versus tenofovir

disoproxil fumarate for the treatment of patients with HBeAg-negative

chronic hepatitis B virus infection: a randomised, double-blind, phase

3, non-inferiority trial[J]. Lancet Gastroenterol Hepatol, 2016, 1 (3):

196-206. DOI: 10.1016/S2468-1253(16)30107-8.

[50] 中華醫(yī)學會肝病學分會肝炎學組 , 中華肝臟病雜志 . 非一線核

苷 ( 酸 ) 類似物經治慢性乙型肝炎患者治療策略調整專家共識

[J]. 中華肝臟病雜志 , 2019, 27 (5) : 343-346. DOI: 10.3760/cma.

j.issn.1007-3418.2019.05.004.

[51] Santini F, Rizvi H, Plodkowski A, et al. Safety and efficacy of re-

treating with immunotherapy after immune-related adverse events

in patients with NSCLC[J]. Cancer Immunol Res, 2018, 6(9): 1093-

1099. DOI: 10.1158/2326-6066.CIR-17-0755.

[52] National Comprehensive Cancer Network. Management of

Immunotherapy-related Toxicities[C]. NCCN Guidelines Version 1,

2020. DOI: 10.6004/jnccn.2020.0012.

[53] Lee Y, Lee J, Lee J, et al. Hepatocellular carcinoma: diagnostic

performance of multidetector CT and MR imaging-a systematic

review and meta-analysis[J]. Radiology, 2015, 275(1): 97-109. DOI:

10.1148/radiol.14140690.

[54] Liu X, Jiang H, Chen J, et al. Gadoxetic aciddisodium-enhanced magnetic

resonance imaging outperformed multidetector computed tomography

in diagnosing small hepatocellular carcinoma:a meta-analysis[J]. Liver

Transpl, 2017, 23(12): 1505-18. DOI: 10.1002/lt.24867.

[55] Eisenhauer E, Therasse P, Bogaerts J, et al. New response evaluation

criteria in solid tumours: revised RECIST guideline[J]. Eur J Cancer,

2009, 45(2): 228-247. DOI: 10.1016/j.ejca.2008.10.026.

[56] Forner A, Ayuso C, Varela M, et al. Evaluation of tumor response

after locoregional therapies in hepatocellular carcinoma: are response

evaluation criteria in solid tumors reliable?[J]. Cancer, 2009, 115(3):

616-623. DOI: 10.1002/cncr.24050.

[57] Lencioni R, Llovet J. Modified RECIST assessment for

hepatocellular carcinoma[J]. Semin Liver Dis, 2010, 30(1): 52-60.

DOI: 10.1055/s-0030-1247132.

[58] Sato Y, Watanabe H, Sone M, et al. Tumor response evaluation

criteria for HCC (hepatocellular carcinoma) treated using TACE:

RECIST version 1.1 and mRECIST: JIVROSG-0602[J]. Ups J Med

Sci, 2013, 118(4): 16-22. DOI: 10.3109/03009734.2012.729104.

[59] Kudo M, Ikeda M, Ueshima K, et al. Response evaluation criteria

in cancer of the liver version 5 (RECICL 2019 revised version)[J].

Hepatol Res, 2019, 49(9): 981-989. DOI: 10.1111/hepr.13394.

[60] Mamdani H, Wu H, Oneil B, et al. Excellent response to Anti-PD-1

therapy in a patient with hepatocellular carcinoma: case report and

review of literature[J]. Discov Med, 2017, 23(128): 331-336. PMID:

28715649.

[61] Grierson P, Crites D, Ruzinova MB, et al. Distinct clinical and

magnetic resonance features of metastatic hepatocellular carcinoma

treated with pembrolizumab: a case report of late response after

pseudoprogression[J]. Hepatol Commun, 2017, 2(2): 148-151. DOI:

10.1002/hep4.1132.

[62] Champiat S, Dercle L, Ammari S. et al. Hyperprogressive disease

is a new pattern of progression in cancer patients treated by anti-

PD-1/PD-L1[J]. Clin Cancer Res, 2017, 23(8): 1920-1928. DOI:

10.1158/1078-0432.CCR-16-1741.

[63] Kato S, Goodman A, Walavalkar V, et al. Hyperprogressors after

immunotherapy: analysis of genomic alterations associated with

accelerated growth rate[J]. Clin Cancer Res, 2017, 23(15): 4242-

4250. DOI: 10.1158/1078-0432.CCR-16-3133.

[64] SBouzid E, Defaucheux C, Karabajakian A, et al. Hyperprogression

during anti-PD-1/PD-L1 therapy in patients with recurrent and/or

metastatic head and neck squamous cell carcinoma[J]. Ann Oncol,

2017, 28(7): 1605-1611. DOI: 10.1093/annonc/mdx178.

[65] Ferrara R, Mezquita L, Texier M. et al. Hyperprogressive disease in

patients with advanced non-small cell lung cancer treated with PD-1/

PD-L1 inhibitors or with singleagent chemotherapy[J]. JAMA Oncol,

2018, 4(11): 1543-1552. DOI: 10.1001/jamaoncol.2018.3676.

[66] Kim C, Kim K, Pyo K, et al. Hyperprogressive disease during PD-1/

PD-L1 blockade in patients with non-small-cell lung cancer[J]. Ann

Oncol, 2019, 30(7): 1104-1113. DOI: 10.1093/annonc/mdz123.

[67] Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for

response criteria for use in trials testing immunotherapeutics[J].

Lancet Oncol, 2017, 18 (3): e143-e152. DOI: 10.1016/S1470-

2045(17)30074-8.

[68] Petrioli R, Mazzei M, Giorgi S, et al. Hyperprogressive disease

in advanced cancer patients treated with nivolumab: a case series

study[J]. Anticancer Drugs, 2020, 31(2): 190-195. DOI: 10.1097/

CAD.0000000000000864.

[69] Tanaka Y, Matsubara O, Asada K, et al. Hyperprogressive disease

after treatment with pembrolizumab in lung adenocarcinoma: an

autopsy case study[J]. Respir Med Case Rep, 2019, 28: 100885.

DOI: 10.1016/j.rmcr.2019.100885.

[70] Wong D, Lee J, Choo S, et al. Hyperprogressive disease in

hepatocellular carcinoma with immune checkpoint inhibitor use: a

case series[J]. Immunotherapy, 2019, 11(3): 167-175. DOI: 10.2217/

imt-2018-0126.

[71] Trevisani F, D’Intino P, Morselli-Labate A, et al. Serum α-fetoprotein

for diagnosis of hepatocellular carcinoma in patients with chronic

liver disease: influence of HBsAg and anti-HCV status[J]. J Hepatol,

2001, 34 (4): 570-575. DOI: 10.1016/s0168-8278(00)00053-2.

[72] Yi X, Yu S, Bao Y. Alpha-fetoprotein-L3 in hepatocellular

carcinoma: a meta-analysis[J]. Clinica Chimica Acta , 2013, 425(21):

212-220. DOI: 10.1016/j.cca.2013.08.005.

[73] Park H, Park J. Clinical significance of AFP and PIVKA- Ⅱ

responses for monitoring treatment outcomes and predicting

prognosis in patients with hepatocellular carcinoma[J]. Biomed Res

Int, 2013, 21(4): 310427. DOI: 10.1155/2013/310427.

[74] 歐美同學會醫(yī)師協(xié)會肝膽分會 , 中國研究性醫(yī)院學會分子診斷

專委會 , 中國臨床腫瘤學會肝癌專委會 , 等 . 肝膽腫瘤分子診斷

臨床應用專家共識 [J]. 中華肝膽外科雜志 , 2020, 26 (2): 81-89.

DOI: 10.3760/cma.j.issn.1007-8118.2020.02.001.